Division of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, WI, USA.
Division of Gastroenterology and Hepatology, University of Miami, Miller School of Medicine, Miami, FL, USA.
Expert Opin Emerg Drugs. 2020 Mar;25(1):59-70. doi: 10.1080/14728214.2020.1735350. Epub 2020 Mar 4.
: Prolonged liver injury results in tissue damage and replacement by extracellular matrix and fibrosis. Cirrhosis represents a leading cause of mortality worldwide and imposes a major financial burden on health-care systems. Fortunately, fibrogenesis has proven to be reversible if halted early, encouraging the development of novel anti-fibrotic agents that may accelerate histological restoration. Preclinical data have elucidated numerous potential therapeutic targets and many anti-fibrotic agents are currently at various stages of clinical research.: The present review summarizes recent clinical data regarding anti-fibrotic drugs including monoclonal antibodies, targeted conjugates, and small molecule agents.: Although undeniable progress has been made in the development of anti-fibrotic agents in recent years, most data currently available are derived from preclinical and early clinical studies. The efficacy and safety of these agents will need to be corroborated by larger clinical trials, some of which are ongoing with results expected in the upcoming years. Combination therapy with agents targeting different pathways of fibrogenesis will also be of great interest for the future and will need to be explored in clinical trials.
: 慢性肝损伤会导致组织损伤和细胞外基质及纤维化的替代。肝硬化是全球主要的死亡原因之一，给医疗保健系统带来了巨大的经济负担。幸运的是，如果早期停止，纤维化已经被证明是可逆的，这鼓励了新型抗纤维化药物的开发，这些药物可能加速组织学恢复。临床前数据已经阐明了许多潜在的治疗靶点，许多抗纤维化药物目前处于不同的临床研究阶段。
: 本综述总结了最近关于抗纤维化药物的临床数据，包括单克隆抗体、靶向缀合物和小分子药物。
: 尽管近年来在抗纤维化药物的开发方面取得了不可否认的进展，但目前大多数数据都来自临床前和早期临床试验。这些药物的疗效和安全性需要更大规模的临床试验来证实，其中一些正在进行中，预计在未来几年内会有结果。针对纤维化不同途径的联合治疗也将是未来的一大关注点，需要在临床试验中进行探索。
